Related Experiment Videos
Therapeutic apheresis: current indication categories
1Oklahoma Blood Institute, Oklahoma City, OK 73104, USA.
Clinical Advances in Hematology & Oncology : H&O
|November 1, 2005
Summary
No abstract available in PubMed .
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
An Evidence-based rationale for a North American commercial bumble bee clean stock certification program.
Journal of pollination ecology·2025
Same author
Endosymbionts that threaten commercially raised and wild bumble bees (<i>Bombus</i> spp.).
Journal of pollination ecology·2025
Same author
Parasites, parasitoids, and hive products that are potentially deleterious to wild and commercially raised bumble bees (<i>Bombus</i> spp.) in North America.
Journal of pollination ecology·2025
Same author
Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4.
Communications biology·2024
Same author
Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia.
Journal of thrombosis and haemostasis : JTH·2023
Same author
Molecular architecture and platelet-activating properties of small immune complexes assembled on intact heparin and their possible involvement in heparin-induced thrombocytopenia.
bioRxiv : the preprint server for biology·2023
Same journal
Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.
Clinical advances in hematology & oncology : H&O·2026
Same journal
Active treatment in high-risk, early-stage CLL or SLL.
Clinical advances in hematology & oncology : H&O·2026
Same journal
Targeting human kallikrein 2 in prostate cancer.
Clinical advances in hematology & oncology : H&O·2026
Same journal
Targeting BRAF V600E mutations in metastatic colorectal cancer.
Clinical advances in hematology & oncology : H&O·2026
Same journal
The development of second-generation KRAS inhibitors.
Clinical advances in hematology & oncology : H&O·2026
Same journal
Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.
Clinical advances in hematology & oncology : H&O·2026